BOULDER — Crestone Inc. has enrolled its first patient for phase 2 of a clinical trial for CRS3123, a drug candidate to treat a type of colon infection called a clostridioides difficile infection, or CDI.
Book your ad in the 2021 Economic Profile & Market Facts publication. The 2020 edition was recently awarded First Place - Best Advertising Special Section by the Colorado Press Association. This summer, be a part of this award-winning publication!
“We are delighted to begin enrolling patients to test this promising novel antibiotic. In addition to its narrow spectrum, CRS3123 also blocks the production of the disease-causing toxins and the formation of spores associated with recurrence,” Crestone medical adviser Dr. Jon Bruss said in a prepared statement.
According to Crestone, CDI is the most common hospital-acquired infection in the United States.
The phase 2, randomized, double-blind, comparator-controlled, multicenter study will evaluate safety and efficacy of two dosages of CRS3123 (200 mg and 400 mg) administered twice-daily compared with antibiotic vancomycin in approximately 100 adults diagnosed with a primary episode or first recurrence of CDI.